Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
EXPANDING THE KNOWLEDGE ON MAMMALIAN ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION (ERAD) (MAMMALIAN ERAD)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Türkiye
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-04-01
End date: 2013-03-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

The misfolded, unfolded or unassembled proteins in the Endoplasmic Reticulum (ER) are degraded by the “Protein Quality Control Mechanism” named as ER-associated degradation (ERAD). In addition to its safeguard role, ERAD can regulate physiological processes that occur in the ER, for example degradation of HMG–CoA reductase, the key enzyme of cholesterol synthesis. ERAD is a multistep process, which starts with substrate (unwanted protein) selection followed by ubiquitination, retrotranslocation, deglycosylation and proteasomal degradation. Aberrant ERAD has implications on several diseases, such as cystic fibrosis, a1-antitrypsin (AAT) deficiency, diabetes, neurodegenerative diseases and cancer. The details of ERAD mechanism are very well known through the studies in S.cerevisiae. Although the general scheme of the pathway is similar, ERAD is more complicated and highly regulated in mammals than in yeast. Studies in yeast suggested existence specialized ERAD pathways depending on the feature of the protein. These pathways are: ERAD-C ( for cytoplasmic misfolded domains), ERAD-L (for luminal misfolded regions), ERAD-M (for membrane misfolded regions). So far, this issue has not been studied in mammalian cells. Here, we intend to identify substrate specific differences present in retrotranslocation machineries in mammalian ERAD using four substrates with different structural features. Additionally, the effect of SVIP (the first identified endogenous ERAD inhibitor) on these substrates, the role of Npl4 in gp78-mediated ERAD and possible functional interaction of gp78 and hHrd1 enzymes will be examined. This research will provide the first information on the substrate specific differences of mammalian ERAD, and also the functional interaction between two important ER-resident E3s: gp78 and Hrd1. Our results on substrate specific ERAD mechanism would contribute to the studies on the therapies of diseases such as cystic fibrosis and AAT deficiency.

Keywords: endoplasmic reticulum associated degradation,erad,ubiquitination,ubiquitin ligase,retrotranslocation,protein folding,misfolding
An Open Platform to Test Integration in new MArkeT DEsigns of massive intermittent energy sources dispersed in several regional power markets (OPTIMATE)

Framework: FP7 — Cooperation
Programme: Energy
Destination: Smart energy networks
Action type: Collaborative project
Countries involved: France,France,Spain,Belgium,France,Belgium,United Kingdom,Denmark,Italy,Germany,Germany
Call:  (FP7-ENERGY-2008-TREN-1, 2008)
Start date: 2009-10-01
End date: 2012-12-31
Duration (months): 39.0
Total project cost (EUR): 4135297.13
EU funding (EUR): 2609688.17
Participants: 14
Project status: CLOSED

Five Transmission System Operators (Belgium, France, Germany and Spain) together with seven RTD performers propose a 3 year research and demonstration project to compare pros and cons of new market designs aiming at the integration of massive intermittent energy sources dispersed in several regional power markets. Under the technical coordination of RTE, they will implement a novel network/system/market modelling approach to provide the consortium with an open simulation platform able to exhibit the comparative benefits of several market design options. Such options may originate either from anyone of the four studied markets or from partners that have already worked for the UK or Danish electric systems. Market participants and TSO are players of such a simulation: each area is represented by aggregated realistic data over one year and system security rules are fulfilled at any time. The demonstration tasks require data with appropriate non disclosure agreements, in order to address first the market behaviour of fully rational players, and next the impact of non optimal behaviours, using agent modelling. Results will be compared (possibly ranked) before being packaged and presented to the TSO community and regulatory authorities for analysis of the platform potential and trustworthiness of the simulation results. This demonstration will be complemented by intensive dissemination activities towards the TSO community within EU27 and beyond, with dedicated trainings to accompany the take-up of the simulation platform. An exploitation agreement is proposed to further improve and expand the platform within the pan European TSO community, beyond the end of this project. Such a platform will help developing technical and regulatory solutions compatible with a virtual single European Grid and regional network management processes by assessing, through combined network and market modelling, the expected outputs of new market designs in support of the 2020 EU27 targets.

Keywords: transmission system,market design,intermitent energy sources,regional network management,network/market modeling tool
Microencapsulation of Islets within Functionalized Peg Hydrogel (DMIOL)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Türkiye
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-05-31
End date: 2013-05-30
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

Diabetes mellitus has a Europe prevalence of approximately 48 million people, including approximately 1 million with Type I diabetes. Despite the availability of exogenous insulin, life expectancy and quality are still diminished by chronic or late complications of the disease. These complications can be mitigated by restoring near-normal levels of glucose. The most effective strategy to do so relies on transplanting islets from donor tissue (in the form of a whole pancreas or isolated islets). Islet transplantation has evolved as a meaningful treatment option for Type I diabetes, but its widespread application has been limited by the need for immunosuppression and limited donor tissue supply. Theoretically, this membrane serves as a mechanical barrier isolating the graft from recipient leukocytes and antibodies while continuing to allow the diffusion of glucose, water, insulin, oxygen, nutrients, and cellular waste.. This research will focus on microencapsulation of islets with functional coats in order to address many of the shortcomings associated with current techniques of immunoisolation. In this project, the technique of interfacial photopolymerization will be employed to immunoisolate islets with functional PEG hydrogel coats. Encapsulation of islets using interfacial photopolymerization is necessary to achieve higher yields to test in vivo function and immunoprotection of islets encapsulated by this method. The hypothesis is that, by employing interfacial photopolymerization along with the techniques presented in this proposal it will be possible to microencapsulate rodent and canine islets in capsules of adequate quantity and consistent quality and that the function of islets microencapsulated by this method will be equivalent to that of unencapsulated islets in environments where allogeneic and xenogenic immunologic rejection are not factors, and superior in models in which rejection is a factor.

Keywords: diabetes,islet,microencapsulation,insulinotropic peptides,mathematical modeling
The Magnetic Milky Way (MAGNETIC_MILKYWAY)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Netherlands
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-03-16
End date: 2013-03-15
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

Magnetic fields pervade the Milky Way and dominate cosmic ray propagation, interstellar medium dynamics and probably star formation. Despite its importance, surprisingly little is known about the strength and structure of the magnetic field in the Galactic disk and halo. The newly developed observational method of Rotation Measure Synthesis will revolutionize our knowledge about the magnetized Galactic ecosystem. This is not only important for Galactic scientists, but is also crucial for interpretation of cosmological data such as the polarized Cosmic Microwave Background or the Epoch of Reionization. A global consortium has been founded to perform the required surveys in both northern and southern hemisphere over an unprecedented wide frequency range. Haverkorn is an active member of the consortium and Principal Investigator of the all-southern-sky survey which is a crucial part of the project. She intends to set up a research group at host institute ASTRON which will become the European center for Galactic magnetic field research. ASTRON is leading the development and exploitation of the innovative next-generation radio telescope LOFAR with exquisite resolution and sensitivity to weak Galactic magnetic fields. Haverkorn's all-northern-sky spectro-polarimetric survey with LOFAR will for the first time characterize the magnetized halo, clarify the origin and evolution of Galactic magnetism, and allow accurate polarized foreground subtraction from cosmological measurements. Haverkorn's large expertise in radio polarimetry will also be very useful in calibration and testing of the telescope. In particular, she will perform an initial polarized calibrator survey which will provide a calibrator catalog for all future LOFAR users, will test the polarization pipeline, and will allow improvement of Galactic magnetic field models.

Keywords: astrophysics,3 d modelling,radiation physics
Identification of the dynamic mechanisms regulating the targeting and clustering of sodium and potassium channels in neurons (CHANNEL TARGETING)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: France
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-07-01
End date: 2013-06-30
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

The electrical excitability is a fundamental property of neurons. Diversity in intrinsic neuronal excitability is generated by the variable expression, subcellular localization, and function of a complex repertoire of ion channels. Dynamic regulation of intrinsic excitability can further alter the behavior of neurons and confer plasticity to neuronal signaling. Aberrant expression, localization, and function of ion channels can result in channel-based pathophysiologies. One of the challenging questions is to understand how neurons regulate the expression and localization of ion channels. The Axon Inital Segment (AIS) and the nodes of Ranvier are key sub-compartments that generate and conduct the action potentials along the axon. The voltage-dependent sodium (Nav) and potassium (Kv) channels are critically concentrated at the AIS and nodes of Ranvier to ensure proper axon potential propagation. Despite the central role of these channels in excitability, the molecular and cellular determinants governing their appropriate targeting and membrane organization are just beginning to emerge. An intricate assembly of adhesion molecules and cytoskeletal scaffold proteins hold Nav and Kv channels in place. However, how such a complex is dynamically regulated is still largely unknown. We recently identified two new processes based on phosphorylation of Nav and Kv complexes by two kinases, casein kinase 2 (CK2) and cyclin-dependant kinase (Cdks). The phosphorylation/dephosphorylation modifications of these channels modify indeed their localization at the AIS. Here, I propose to analyze, using a multidisciplinary approach, the respective role of CK2 and Cdks signaling pathways on dynamic targeting/assembly of Nav1 and Kv1 channels at the AIS and in the node of Ranvier. The end-results of this proposal should provide new insights into the mechanisms involved in the dynamic regulation of excitability and opens new paths to better understand defects leading to neuronal dysfunction.

Keywords: health sciences,ion channels,axonal targeting,node of ranvier,phosphorylation
Novel therapeutic antibodies for multiple myeloma (MMSC)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Italy
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-10-01
End date: 2013-09-30
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 2
Project status: CLOSED

Multiple Myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3 years. A critical step towards the development of more effective therapies is the identification of dominantly acting oncogenes. We have implemented an integrated oncogenomic approach that utilizes high-resolution gene-specific array-CGH and comprehensive expression profiling to identify the spectrum of genetic alterations in a large panel of MM cell lines (n=46) and annotated primary tumors (n=65). These efforts have uncovered a strikingly high number of novel recurrent focal amplifications and deletions. To select the most critical amplicons, a stringent filtering algorithm that takes in account the amplification level, recurrence and the presence of similar lesions in an extensive array-CGH database of more than 600 tumors and cell lines from different cancer types yielded 13 highly-selected amplicons. Within these, 117 genes demonstrated significant upregulation when compared with normal plasma cells, with 28 genes considered potential targets for Monoclonal Antibodies based on their structural features. This dataset will be prioritized by key parameters including oncogenic validation assays and in vivo testing. The ultimate goal of this proposal is to provide a list of functionally validated antibody targets, which can be enlisted into therapeutic monoclonal antibody development.

Keywords: myeloma,genomics,screening,array comparative genomic hybridization (acgh),gene expression profiling,oncogene,therapeutic monoclonal antibodies
Recovered Fuels combined with Biomass (RECOMBIO)

Framework: FP7 — Cooperation
Programme: Energy
Destination: Renewable electricity generation
Action type: Collaborative project
Countries involved: Germany,Finland,Finland,Germany,Germany,Netherlands,European organisations area,Poland,Germany,Norway
Call:  (FP7-ENERGY-2008-TREN-1, 2008)
Start date: 2010-01-01
End date: 2013-12-31
Duration (months): 48.0
Total project cost (EUR): 6382396.0
EU funding (EUR): 4040074.0
Participants: 14
Project status: CLOSED

The RECOMBIO project is concerned with developments and demonstrations of innovative approaches to the high efficient co-utilisation of low quality biomasses and Solid Recovered Fuels (SRF) produced from municipal solid waste (MSW) for electricity production and combined heat and power (CHP) usage, at competitive costs, high plant availability, and advanced energy efficiency. The production of quality controlled biomass, bio-residues, SRF, and an intelligent fuel management of the producer and user is essential for the project success, which will also be investigated and demonstrated in the frame of the project. The exploitation potential of the results are significant for future biomass power generation or CHP projects, due to the fact that different technologies, such as circulating and bubbling fluidised beds (CFB, BFB), meeting best available techniques (BAT) standards are incorporated to demonstrate the highly efficient utilisation chain for the intelligent co-utilisation of low quality biomass and SRF. Under the RECOMBIO project it is proposed to perform a number of demonstrations of relevant SRF production and utilisation technologies with new developments, substantial investments, long-term monitoring, assessment of the key technical aspects, Life Cycle Analyses (LCA), and enhanced material recycling. The achievement in exploitation and transfer of knowledge and technology gained in the project will occur through the normal business activities of utilities, producers, and manufactures involved. Along with providing valuable information to support future decisions by key utilities, manufacturers, authorities, etc., the results will assist the European Commission in decision making regarding re-examining targets set in the European Union’s Landfill Directive and strengthen the recovery option in the waste hierarchy of the Waste Directive. The overall objective is to enhance the future use of biomass and SRF, facilitating the creation of a sustainable energy market across Europe and demonstrating the use of short-term available BAT technologies that will reduce CO2 emissions.

Keywords: recovered fuels,biomass,on-line analysis,sensor based sorting technology,co-combustion,power plant,lca
Bioactive compounds from seafood byproducts (BIOSEAFOOD)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Iceland
Call:  (FP7-PEOPLE-IRG-2008, 2008)
Start date: 2009-04-01
End date: 2013-03-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

This project aims to follow the fate of three groups of aquatic bioactive compound from raw material to active cellular site; long-chain omega-3 polyunsaturated fatty acids (omega-3 PUFA), fish peptides and seaweed polyphenols. The focus is to study if there are bioactivity losses prior to ingestion (i.e. during storage in a food product) or during gastrointestinal (GI) digestion and investigate wether there may be potential positive/deleterious effects of the compounds after digestion. This work will be done in collaboration with Chalmers University and University of Florida, USA. Omega-3 PUFA are highly prone to oxidation. No research has been done to clarify their oxidation under GI passage, which may be highly pro-oxidative. Few studies have linked putative ex vivo PUFA oxidation in food products with changes in bioactive responses after digestion and cellular uptake. Also, interaction between the PUFA and peptides/polyphenols in this chain of events is a novel research focus. The impact of dosage and food matrix formulation for the interplay addressed will be of special importance in development of safe functional food products with aquati bioactives. The project is divided into four work packages: (1) Production/analysis of three bioactive compounds, (2) Stability of bioactives alone or in a food model, (3) GI-oxidation/antioxidation of omega-3 PUFA, peptides and polyphenols using static/dynamic models, and (4) Effect of bioactives digests on antioxidative/oxidative and anti-inflammatory responses in cells. The outcomes will aid toxicologists to develop biomarkers and validate safety of bioactives, nutritionists to design dietary guidelines, food industry to optimizing functional food product formulations and the public to better understanding how to eat to remain healthy.

Keywords: bioactive compounds,marine,oxidation,functional food,toxic substances,natural sciences
Sophisticated Well-Targeted Therapeutic Entities based on Biologically Compatible Ti(IV) Active Cores and Building Blocks (SMARTDRUGENTITIES)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Materials and Synthesis
Countries involved: Israel
Call:  (ERC-2009-StG, 2009)
Start date: 2009-10-01
End date: 2014-09-30
Duration (months): 60.0
Total project cost (EUR): 1400000.0
EU funding (EUR): 1400000.0
Participants: 1
Project status: CLOSED

I propose to develop sophisticated anti-tumor agents targeted particularly to the location of activity. My team has recently introduced a new family of Ti(IV) complexes that demonstrates higher activity than known compounds with substantially higher stability and defined hydrolytic behavior, properties that were found to be essential. I propose to study various derivatives and identify the parameters affecting activity, including steric and electronic effects, enantiomeric purity, ligand lability etc., and elucidation various mechanistic aspects of reactivity. More importantly, I propose to construct pH-sensitive transport units that will allow protection of the sensitive active species throughout their delivery and release only near the target location based on the variable pH conditions of different human tissues. In particular, unique spherical molecules held together by metal-ligand interactions will be prepared. The building blocks will consist of the planar ligands of C3-axis bound to three biocompatible Ti(IV) ions each with defined angles and geometry. The resulting spherical compounds will be utilized to encapsulate the active complexes and release them upon hydrolysis at the desired pH based on the pH-dependent hydrolysis pattern already established for related compounds. Preliminary calculations have confirmed the possibility of forming these compounds, which are particularly matching in their expected size to encapsulate our complexes. Larger spheres will also be prepared as cavities for larger molecules, which may be linked together for the delivery of multiple drugs. These compounds may find applications in various areas where a protected environment or delivery of sensitive compounds is required, such as in gene therapy, nano-technology, and catalysis.

Keywords: ti(iv) complexes,phenolato ligands,cytotoxicity,drug delivery